Literature DB >> 7992474

Antiviral studies of feline infectious peritonitis virus in vitro.

J E Barlough1, B L Shacklett.   

Abstract

Sixteen compounds were tested for their ability to inhibit the replication in vitro of feline infectious peritonitis virus (FIPV), a coronavirus that causes a lethal, immunologically mediated illness in domestic and exotic cats. Six of the compounds, when incubated with cells and titrations of the virus, were found to reduce the virus titres by 0.401 to 0.833 log10 (P < 0.05), using the cytopathic effect as endpoint. Further inhibition studies were performed to determine the 50 per cent effective dose (ED50) levels for these six compounds. Selectivity indices (50 per cent cytotoxic dose [CD50]/ED50) provided the following order of antiviral activity: pyrazofuin > 6-azauridine > 3-deazaguanosine > hygromycin B > fusidic acid > dipyridamole. Compounds which had no statistically significant effect on FIPV in the same assay were caffeic acid, carbodine, 3-deazauridine, 5-fluoroorotic acid, 5-fluorouracil, D(+)glucosamine, indomethacin, D-penicillamine, rhodamine and taurine.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7992474     DOI: 10.1136/vr.135.8.177

Source DB:  PubMed          Journal:  Vet Rec        ISSN: 0042-4900            Impact factor:   2.695


  15 in total

1.  Inhibition of human coronavirus NL63 infection at early stages of the replication cycle.

Authors:  Krzysztof Pyrc; Berend Jan Bosch; Ben Berkhout; Maarten F Jebbink; Ronald Dijkman; Peter Rottier; Lia van der Hoek
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

2.  Antisense morpholino-oligomers directed against the 5' end of the genome inhibit coronavirus proliferation and growth.

Authors:  Benjamin W Neuman; David A Stein; Andrew D Kroeker; Amy D Paulino; Hong M Moulton; Patrick L Iversen; Michael J Buchmeier
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

Review 3.  A review of feline infectious peritonitis virus infection: 1963-2008.

Authors:  Niels C Pedersen
Journal:  J Feline Med Surg       Date:  2009-02-28       Impact factor: 2.015

4.  Identification and characterisation of small molecule inhibitors of feline coronavirus replication.

Authors:  Phillip McDonagh; Paul A Sheehy; Jacqueline M Norris
Journal:  Vet Microbiol       Date:  2014-11-04       Impact factor: 3.293

5.  In vitro inhibition of feline coronavirus replication by small interfering RNAs.

Authors:  Phillip McDonagh; Paul A Sheehy; Jacqueline M Norris
Journal:  Vet Microbiol       Date:  2011-02-01       Impact factor: 3.293

6.  A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs.

Authors:  Jianzhong Cao; J Craig Forrest; Xuming Zhang
Journal:  Antiviral Res       Date:  2014-11-28       Impact factor: 5.970

7.  Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients.

Authors:  Kholoud F Aliter; Rami A Al-Horani
Journal:  Curr Pharm Des       Date:  2021       Impact factor: 3.116

8.  Potent inhibition of feline coronaviruses with peptidyl compounds targeting coronavirus 3C-like protease.

Authors:  Yunjeong Kim; Sivakoteswara Rao Mandadapu; William C Groutas; Kyeong-Ok Chang
Journal:  Antiviral Res       Date:  2012-11-28       Impact factor: 5.970

9.  Effect of chloroquine on feline infectious peritonitis virus infection in vitro and in vivo.

Authors:  Tomomi Takano; Yasuichiroh Katoh; Tomoyoshi Doki; Tsutomu Hohdatsu
Journal:  Antiviral Res       Date:  2013-05-03       Impact factor: 5.970

10.  Generation, characterization and therapeutic potential of anti-feline TNF-alpha MAbs for feline infectious peritonitis.

Authors:  Tomoyoshi Doki; Tomomi Takano; Yuri Nishiyama; Michiyo Nakamura; Tsutomu Hohdatsu
Journal:  Res Vet Sci       Date:  2013-09-19       Impact factor: 2.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.